How much funding has Corxel raised?

Corxel has raised $581.5M in total funding, most recently a Series B round.

Who are Corxel's investors?

Corxel's investors include RTW Investments, SR One, Leaps by Bayer, Hengdian Group Capital, TCGX, RA Capital Management.

Where is Corxel headquartered?

Corxel is headquartered in New Jersey, United States.

Corxel

Developing innovative cardiometabolic therapies globally

United States · Founded 2019 · $581.5M raised

Biotech

Headquarters: New Jersey
Employees: 51–200
Founded: 2019
Business Model: B2B

Total Funding: $581.5M
Last Round: $82.5M Series BJan 2026
Rounds: 4

About

CORXEL (formerly Ji Xing Pharmaceuticals, founded 2019) is a clinical-stage biopharmaceutical company headquartered in the United States and China, focused on developing innovative therapies for patients with cardiometabolic conditions. The company's strategy centers on identifying and in-licensing clinical-stage assets against validated cardiometabolic targets — including obesity, type 2 diabetes, hypertension, and acute cardiovascular events — and advancing them through mid- and late-stage development across global and regional pathways. Its lead program, CX11, is an oral small-molecule GLP-1 receptor agonist in Phase II development for obesity and type 2 diabetes. In January 2026, CORXEL completed a $287 million Series D1 financing to advance its cardiometabolic pipeline.

Summary

Corxel is a Biotech company based in United States, founded in 2019. It has raised $581.5M in total across 4 rounds, most recently a $82.5M Series B round in Jan 2026. Investors include RTW Investments, SR One and Leaps by Bayer.